Triple negative breast cancer: looking for the missing link between biology and treatments
about
Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular backgroundTumour biomarkers: homeostasis as a novel prognostic indicatorFAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistanceTumor-Specific Peptide, Selected from a Phage Peptide Library, Enhances Antitumor Activity of LactaptinAntitumor effects of naturally occurring cardiac glycosides convallatoxin and peruvoside on human ER+ and triple-negative breast cancersSalicylate •Phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells.Morusin suppresses breast cancer cell growth in vitro and in vivo through C/EBPβ and PPARγ mediated lipoapoptosis.Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).Inhibition of signaling between human CXCR4 and zebrafish ligands by the small molecule IT1t impairs the formation of triple-negative breast cancer early metastases in a zebrafish xenograft modelThe autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair.Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapyQuantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer.Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancerBlocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancerTriple negative breast cancer development can be selectively suppressed by sustaining an elevated level of cellular cyclic AMP through simultaneously blocking its efflux and decomposition.BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.Synthesis and Antitumor Activity of New Group 3 Metallocene Complexes.In vivo magnetic resonance imaging investigating the development of experimental brain metastases due to triple negative breast cancer.Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive Breast Cancer.Metastatic breast cancer: The Odyssey of personalization.Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.Differences in elongation of very long chain fatty acids and fatty acid metabolism between triple-negative and hormone receptor-positive breast cancer.Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer.Calpain-1 Expression in Triple-Negative Breast Cancer: A Potential Prognostic Factor Independent of the Proliferative/Apoptotic Index.Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes.Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.Anti-tumorigenic effects of a novel digitoxin derivative on both estrogen receptor-positive and triple-negative breast cancer cells.Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems.Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-κB signaling pathway.BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.Silencing of TGIF sensitizes MDA-MB-231 human breast cancer cells to cisplatin-induced apoptosis.Targeting intracellular B2 receptors using novel cell-penetrating antagonists to arrest growth and induce apoptosis in human triple-negative breast cancer.Prognostic implications of securin expression and sub-cellular localization in human breast cancer.microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers.PET Imaging on Dynamic Metabolic Changes after Combination Therapy of Paclitaxel and the Traditional Chinese Medicine in Breast Cancer-Bearing Mice.Targeted therapy of triple negative MDA-MB-468 breast cancer with curcumin delivered by epidermal growth factor-conjugated phospholipid nanoparticles.
P2860
Q26745416-62D5FAAC-BC18-4B92-B9C2-FE1A725DFFEDQ28069898-CAC05AB4-FDAF-485C-9C6E-A6431168AB20Q28077347-8C4B3E00-984A-4052-B1A0-0A725A6E1C02Q28553463-75022E88-17B9-4D84-B454-B58BD45AB21DQ29248485-BA2DC3F5-DF62-4055-A44E-108018A56F26Q33728161-558E5A73-88F9-4619-94AF-B39DA9182A29Q36252606-5EE74F78-26BD-4B1F-A400-67C1FA23F207Q36265028-5E517D1A-4C70-4CF1-8F8D-2FEF68175604Q36627752-0EA0A32C-B5ED-4FF6-B158-94E9F29991CBQ36893137-DD5BF2ED-6EA7-4136-8252-837F0BCB6367Q37362715-ED88C2A3-2E25-4A6C-BF16-2E5D6439DD27Q37376754-D9E379BA-3099-4B76-B7B9-9BC2F2C83B91Q37426564-F7582A91-11A6-441C-BD05-3F414B7E79ABQ37536680-EE62953D-ED03-493F-BA87-D21E5428FA80Q37699405-6B164902-84BB-4356-8260-5DAA74F0D808Q37705790-99CDB5DA-3EDB-468F-9401-A9BBEF3F4E82Q38710048-0099B35C-ADC9-4184-ACF9-32AA14E8B93CQ38720211-BF626C82-BFFD-4CA7-8FD1-5F853DCE285DQ38722836-707F3CCF-DA9A-4125-9FFA-E210980DE48BQ38901163-76B4E394-1044-494F-A180-F06797601924Q38925022-62A20C49-C6DF-4C60-A37C-6B0FBAA315CDQ38935156-51EAACA9-5638-484A-A2B1-DD87C4CC48BAQ41078110-1901053B-6FB3-435D-81F8-19CD4592282BQ41078694-A565DABB-0231-4BA5-A346-F88EAAA0927FQ41557835-BA76ADEA-37B4-49CD-BD33-52FDA390C775Q41701909-E91073F9-7C36-4DC1-B4AF-C43A123F89A3Q42177754-DE00BE06-39BB-4BB7-A7B1-36F485025DEFQ42275833-8E41A2F6-0E79-4EF1-BA5C-D5F6F1162957Q46237958-E2F05D95-4881-42C3-B5EF-D94BC19EBABAQ46349486-7D90DDBE-53D6-4378-81B7-4148B984F64FQ47123785-87112D0D-C7B5-493D-A8CD-E2E14A6D0018Q48121718-02F0AB4F-8ABF-4D1D-AB67-CE5DBAEFB80EQ48906011-CA887614-E13F-4A8E-A346-979CB015D478Q49875247-AC5447E9-F842-478B-95FC-942943BC03ECQ52668195-54BB83AA-FDD2-4958-945C-E4FCC9B9D541Q52880311-534E37E8-0E35-46C9-9B68-705C01822375Q52932292-A28B7418-7EB9-42D8-9DF5-177DDA6C2208Q54977482-A4292683-445A-42A1-A1AE-0735E941ABC4Q54989589-085B80E7-0090-41CE-B809-DC5993F42C90Q55103330-3DDD9D62-6E76-439D-9037-77C2B376110F
P2860
Triple negative breast cancer: looking for the missing link between biology and treatments
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Triple negative breast cancer: ...... between biology and treatments
@ast
Triple negative breast cancer: ...... between biology and treatments
@en
Triple negative breast cancer: ...... between biology and treatments
@nl
type
label
Triple negative breast cancer: ...... between biology and treatments
@ast
Triple negative breast cancer: ...... between biology and treatments
@en
Triple negative breast cancer: ...... between biology and treatments
@nl
prefLabel
Triple negative breast cancer: ...... between biology and treatments
@ast
Triple negative breast cancer: ...... between biology and treatments
@en
Triple negative breast cancer: ...... between biology and treatments
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
Triple negative breast cancer: ...... between biology and treatments
@en
P2093
Carmela Saturnino
Claudio Siani
Emanuela Esposito
Giuseppe Frasci
Massimiliano D'Aiuto
P2860
P304
P3181
P356
10.18632/ONCOTARGET.5306
P407
P577
2015-09-29T00:00:00Z